Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hyperactive PASylated DNase I
- Development stage
- Preclinical
- Lead developer
- XL-protein
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Hyperactive PASylated DNase I is an investigational biologic therapeutic being developed by XL-protein in collaboration with Rentschler Biopharma. The drug consists of a hyperactive variant of recombinant human deoxyribonuclease I (DNase I) that has been modified using XL-protein's proprietary PASylation technology. This technology involves the genetic fusion of the enzyme with a defined polypeptide sequence of proline, alanine, and serine (PAS), which significantly increases the enzyme's systemic half-life and enhances its catalytic activity compared to the wild-type enzyme. The therapeutic is designed to target and degrade extracellular DNA, including neutrophil extracellular traps (NETs), which are known to drive inflammation and increase mucus viscosity in various pathological conditions. It is currently in preclinical development for the treatment of cystic fibrosis, autoimmune diseases, and other chronic inflammatory disorders.
- Other names
- PASylated DNase IPASylated deoxyribonuclease Ihyperactive PASylated recombinant human DNase I
02
Targets
cfDNA (Cell-free DNA)
Beyond the preview
Go deeper on hyperactive PASylated DNase I.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hyperactive PASylated DNase I.